Dr. Berghmans and Dr. van Bouckenooghe were the worldwide first users of the LEGFLOW 018 on a Patient with CLI disease. The product was used in BtK and showed excellent performance. In addition the patient received a DCB therapy with our LEGFLOW OTW in the SFA as well.
CARDIONOVUM GmbH today announced the completion of enrollment of the RAPID trial. Results will be used to further support the safety and effectiveness of CARDIONOVUM’s Legflow® drug-coated balloon (DCB).